We are live on ! Find out more
CGTX icon

Cognition Therapeutics

69 hedge funds and large institutions have $28.7M invested in Cognition Therapeutics in 2025 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 23 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

721% more capital invested

Capital invested by funds: $3.5M → $28.7M (+$25.2M)

475% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 4

288% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 8

44% more funds holding

Funds holding: 4869 (+21)

10.83% more ownership

Funds ownership: 18.1%28.93% (+11%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
69
Holders Change
+21
Holders Change %
+43.75%
% of All Funds
0.91%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
31
Increased
23
Reduced
4
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
76
Goldman Sachs
New York
-$4.53K -14,635 Closed
AC
77
Apella Capital
Connecticut
-$6.48K -11,200 Closed

CGTX Hedge Fund Activity: Q3 2025 in Review

69 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q3 2025, worth a combined $28.7M — up 721% from $3.5M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new CGTX positions and 8 closed out — a net gain of 23 holders — while 23 added to existing stakes and 4 trimmed.

The largest buyer was Davenport & Co, opening a new position worth an estimated $3.67M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $216K sold.

  • 69 institutional investors held Cognition Therapeutics (CGTX) as of Q3 2025, up from 48 in Q2 2025.
  • Funds reported $28.7M of Cognition Therapeutics stock for Q3 2025, up 721% quarter-over-quarter.
  • 31 funds opened new Cognition Therapeutics positions in Q3 2025 and 8 closed out, a net change of +23 holders.
  • The largest Cognition Therapeutics buyer in Q3 2025 was Davenport & Co, an estimated $3.67M added.
  • The largest Cognition Therapeutics seller in Q3 2025 was Acadian Asset Management, an estimated $216K sold.

Based on aggregated 13F filings for Q3 2025.